Novo Nordisk Inventory 2010-2024 | NVO

Novo Nordisk inventory from 2010 to 2024. Inventory can be defined as the total value of inventories in all stages of completion.
  • Novo Nordisk inventory for the quarter ending September 30, 2024 was $5.593B, a 29.71% increase year-over-year.
  • Novo Nordisk inventory for 2023 was $4.619B, a 33.75% increase from 2022.
  • Novo Nordisk inventory for 2022 was $3.453B, a 10.62% increase from 2021.
  • Novo Nordisk inventory for 2021 was $3.122B, a 9.93% increase from 2020.
Novo Nordisk Annual Inventory
(Millions of US $)
2023 $4,619
2022 $3,453
2021 $3,122
2020 $2,840
2019 $2,644
2018 $2,498
2017 $2,335
2016 $2,131
2015 $1,898
2014 $2,025
2013 $1,701
2012 $1,649
2011 $1,763
2010 $1,728
2009 $1,876
Novo Nordisk Quarterly Inventory
(Millions of US $)
2024-09-30 $5,593
2024-06-30 $5,246
2024-03-31 $4,892
2023-12-31 $4,619
2023-09-30 $4,312
2023-06-30 $4,094
2023-03-31 $3,691
2022-12-31 $3,453
2022-09-30 $3,142
2022-06-30 $3,104
2022-03-31 $3,060
2021-12-31 $3,122
2021-09-30 $2,997
2021-06-30 $3,051
2021-03-31 $3,024
2020-12-31 $2,840
2020-09-30 $2,842
2020-06-30 $2,630
2020-03-31 $2,549
2019-12-31 $2,644
2019-09-30 $2,609
2019-06-30 $2,580
2019-03-31 $2,563
2018-12-31 $2,498
2018-09-30 $2,484
2018-06-30 $2,583
2018-03-31 $2,620
2017-12-31 $2,335
2017-09-30 $2,406
2017-06-30 $2,223
2017-03-31 $2,157
2016-12-31 $2,131
2016-09-30 $2,138
2016-06-30 $2,071
2016-03-31 $1,922
2015-12-31 $1,898
2015-09-30 $1,903
2015-06-30 $1,901
2015-03-31 $1,863
2014-12-31 $2,025
2014-09-30 $2,009
2014-06-30 $1,966
2014-03-31 $1,892
2013-12-31 $1,701
2013-09-30 $1,659
2013-06-30 $1,692
2013-03-31 $1,699
2012-12-31 $1,649
2012-09-30 $1,582
2012-06-30 $1,630
2012-03-31 $1,683
2011-12-31 $1,763
2011-09-30 $1,720
2011-06-30 $1,735
2011-03-31 $1,643
2010-12-31 $1,728
2010-09-30 $1,689
2010-06-30 $1,718
2010-03-31 $1,911
2009-12-31 $1,876
2009-09-30 $1,872
2009-06-30 $1,811
2009-03-31 $1,738
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $481.063B $33.708B
Bagsv?rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $789.394B 81.76
Johnson & Johnson (JNJ) United States $374.313B 15.18
AbbVie (ABBV) United States $352.544B 18.56
Merck (MRK) United States $260.350B 17.30
Novartis AG (NVS) Switzerland $217.584B 14.46
AstraZeneca (AZN) United Kingdom $199.957B 17.81
Pfizer (PFE) United States $151.422B 10.36
Sanofi (SNY) $130.241B 11.80
Innoviva (INVA) United States $1.263B 10.51